Cell viability was determined in AML cell lines treated with increasing dosages of single compounds and in combination treatments using the HSP90 inhibitor PU-H71 and a variety of targeted therapies including the BCL2 inhibitor venetoclax and the MCL1 inhibitor S63845. The gene discussed is MCL1; the disease is acute myeloid leukemia.